Key clinical point: Three months of DAPT was noninferior to a historical cohort of longer DAPT after implantation of the Ultimaster bioresorbable polymer sirolimus-eluting stent in net adverse clinical events.
Major finding: The primary endpoint occurred in 4.3% of patients in the MODEL U-SES group, compared with 5.7% of patients in the CENTURY II BP-SES group, a difference of –3.17%, which demonstrated noninferiority of the trial (P less than .001).
Study details: A prospective, single-arm registry trial of 1,695 patients in Japan.
Disclosures: Terumo sponsored the trial. Dr. Kozuma serves on the scientific advisory boards for and has received honoraria from Terumo, Abbott Vascular Japan, Boston Scientific Japan, Daiichi-Sankyo, Sanofi, Bayer, Boehringer Ingelheim and Bristol-Meyers Squibb.
Kozuma K et al. TCT 2019, late-breaking presentation.